Empowered Patient Podcast

Dr. Thomas Young is the Founder and Chief Medical Officer of nView Health, a behavioral health technology company providing tools for physicians and researchers to help diagnose psychiatric disorders accurately and efficiently determine treatment options. In addition, the nView Health tools allow tracking and following outcomes to determine if the right drugs have been prescribed and if the cognitive behavioral therapy intervention is working.

Thomas elaborates, "Mental health is a large category. I think what people have to understand is, kind of the old rule when I was teaching in medicine, is that 50% of the people that come into a doctor's office for some sort of physical ailment also have a mental health disorder. One in five Americans has depression at some point in their life, and that's a significant number of people. Anxiety is climbing in children. Eating disorders are shooting up at hockey stick rates."

"What nView Health does, we believe strongly that the system requires the ability to create an initial ability for people to be screened at every level including children. Providers of all types, primary care providers, nurse practitioners, pediatricians, and others, can give a simple screening test. I can ask a few questions, and I can get some information that helps me understand this patient's behavioral health status."

"Secondary to that is the ability to then arm the primary care community with the right tools to be able to make the right diagnostic decisions. Our tools don't make diagnoses. Our tools help and assist a provider in collecting the right data so that they can make an appropriate decision. Because what we know is that early diagnosis leads to early treatment, which leads to better outcomes."

@nViewHealth #BehavioralHealth #MentalHealth #ValueBasedCare #DigitalWorkFlows #ActionableData #HealthyMindsStartHere

nviewhealth.com

Listen to the podcast here

Dr. Thomas Young is the Founder and Chief Medical Officer of nView Health, a behavioral health technology company providing tools for physicians and researchers to help diagnose psychiatric disorders accurately and efficiently determine treatment options. In addition, the nView Health tools allow tracking and following outcomes to determine if the right drugs have been prescribed and if the cognitive behavioral therapy intervention is working.

Thomas elaborates, "Mental health is a large category. I think what people have to understand is, kind of the old rule when I was teaching in medicine, is that 50% of the people that come into a doctor's office for some sort of physical ailment also have a mental health disorder. One in five Americans has depression at some point in their life, and that's a significant number of people. Anxiety is climbing in children. Eating disorders are shooting up at hockey stick rates."

"What nView Health does, we believe strongly that the system requires the ability to create an initial ability for people to be screened at every level including children. Providers of all types, primary care providers, nurse practitioners, pediatricians, and others, can give a simple screening test. I can ask a few questions, and I can get some information that helps me understand this patient's behavioral health status."

"Secondary to that is the ability to then arm the primary care community with the right tools to be able to make the right diagnostic decisions. Our tools don't make diagnoses. Our tools help and assist a provider in collecting the right data so that they can make an appropriate decision. Because what we know is that early diagnosis leads to early treatment, which leads to better outcomes."

@nViewHealth #BehavioralHealth #MentalHealth #ValueBasedCare #DigitalWorkFlows #ActionableData #HealthyMindsStartHere

nviewhealth.com

Download the transcript here

Shuo Qiao is the Co-Founder and CTO of Moving Analytics, a digital health company focusing on cardiovascular health and providing alternatives to traditional cardiac services. While many devices measure blood pressure and monitor activity, using them can be time-consuming and provide inaccurate readings. Shou points to clinical evidence that home-based cardiac rehabilitation with remote sensing support is as safe and effective as in-person care. The challenge is getting providers and payers to understand how this approach can significantly benefit them as well as patients.

Shuo explains, "What we are using currently is from one of our device providers. They provide a heart monitor and weighing scale that basically just does the measurements. They will automatically transfer the data through 3G network to our server. I would say there's zero set-up for the patient. They just get the device, and they just measure their blood pressure and weight. That's it. When it's done, data automatically uploads. No set-up whatsoever. Those are the things that we usually use."

"On top of that, we also have a smart activity tracker that you put on the wrist. It can help you monitor your daily tasks, how much you exercise, along with your heart rate, and things like that. It's super helpful as well."

@MovingAnalytics #Telehealth #DigitalHealth #VirtualCare #CardiacRehabilitation #CardiacRehab #ActivityTracker

movinganalytics.com

Download the transcript here

Shuo Qiao is the Co-Founder and CTO of Moving Analytics, a digital health company focusing on cardiovascular health and providing alternatives to traditional cardiac services. While many devices measure blood pressure and monitor activity, using them can be time-consuming and provide inaccurate readings. Shou points to clinical evidence that home-based cardiac rehabilitation with remote sensing support is as safe and effective as in-person care. The challenge is getting providers and payers to understand how this approach can significantly benefit them as well as patients.

Shuo explains, "What we are using currently is from one of our device providers. They provide a heart monitor and weighing scale that basically just does the measurements. They will automatically transfer the data through 3G network to our server. I would say there's zero set-up for the patient. They just get the device, and they just measure their blood pressure and weight. That's it. When it's done, data automatically uploads. No set-up whatsoever. Those are the things that we usually use."

"On top of that, we also have a smart activity tracker that you put on the wrist. It can help you monitor your daily tasks, how much you exercise, along with your heart rate, and things like that. It's super helpful as well."

@MovingAnalytics #Telehealth #DigitalHealth #VirtualCare #CardiacRehabilitation #CardiacRehab #ActivityTracker

movinganalytics.com

Download the transcript here

Dr. Anthony Japour is the Chief Executive Officer and President at iTolerance, an early-stage privately-held regenerative medicine company. Currently, if a patient receives a pancreatic islet transplant to treat type 1 diabetes, there is a need for lifelong immune suppression. The technology that iTolerance is developing leverages the protein Fas Ligand to enable implantation without the need to be immune suppressed to suppress the body from rejecting the foreign tissue.

Anthony explains, "Our treatment does allow for local immune tolerance, so around the area of the cells, organoid, or tissue. It allows it to be accepted without the body rejecting it by inducing what's called local immune tolerance. This does not affect the systemic immune system, only the local immune system. And it has not been done in humans yet. It's been tested both in rodent model rats as well as in monkeys. And in both models, we can cure type 1 diabetes."

"The technology of our product came from Georgia Tech University in Atlanta, as well as the University of Louisville in Kentucky. And the researcher that was there is now at the University of Missouri in Columbia, Missouri. This is Dr. Andrés García at Georgia Tech, who is a world-renowned expert in biomaterials. He's been developing the micro gel treatment for a period of time and is a very well-respected researcher. Also, Dr. Haval Shirwan, who is an immunologist, has been working with the FasL protein for roughly 20 or 25 years."

@iTolerance_Inc #RegenerativeMedicine #Transplants #PancreaticIsletTransplant #Diabetes #Type1Diabetes #ImmuneSuppressiveDrugs #ImmuneTolerance #Apoptosis #FasL #FasLigand

iTolerance.com

Listen to the podcast here

Dr. Anthony Japour is the Chief Executive Officer and President at iTolerance, an early-stage privately-held regenerative medicine company. Currently, if a patient receives a pancreatic islet transplant to treat type 1 diabetes, there is a need for lifelong immune suppression. The technology that iTolerance is developing leverages the protein Fas Ligand to enable implantation without the need to be immune suppressed to suppress the body from rejecting the foreign tissue.

Anthony explains, "Our treatment does allow for local immune tolerance, so around the area of the cells, organoid, or tissue. It allows it to be accepted without the body rejecting it by inducing what's called local immune tolerance. This does not affect the systemic immune system, only the local immune system. And it has not been done in humans yet. It's been tested both in rodent model rats as well as in monkeys. And in both models, we can cure type 1 diabetes."

"The technology of our product came from Georgia Tech University in Atlanta, as well as the University of Louisville in Kentucky. And the researcher that was there is now at the University of Missouri in Columbia, Missouri. This is Dr. Andrés García at Georgia Tech, who is a world-renowned expert in biomaterials. He's been developing the micro gel treatment for a period of time and is a very well-respected researcher. Also, Dr. Haval Shirwan, who is an immunologist, has been working with the FasL protein for roughly 20 or 25 years."

@iTolerance_Inc #RegenerativeMedicine #Transplants #PancreaticIsletTransplant #Diabetes #Type1Diabetes #ImmuneSuppressiveDrugs #ImmuneTolerance #Apoptosis #FasL #FasLigand

iTolerance.com

Download the transcript here

Spiro Rombotis is the CEO of Cyclacel, which is identifying biomarkers relevant to their drug fadraciclib's mechanism to increase the chance for success in trials for a wide range of cancers. Cyclacel has seen activity of fadra as a single agent in phase one patients with women's cancers like endometrial, ovarian, and breast cancers, and lymphomas, liver cancer, and colorectal cancer.

Spiro explains, "Before the pandemic, we had an intravenous version of fadra administered to patients in a single center study at Dana-Farber Cancer Institute in Boston. And although the drug was active in these patients, it is clear during the pandemic and now, at hopefully the tail end of the pandemic, that oral therapies have dramatic advantages. Not only because patients don't have to be exposed to the virus, which is not a very good idea for a cancer patient who is more vulnerable than the general population, but also because of the ability and convenience of receiving a drug orally and staying at home."

"We take patients regardless of tumor type, the anatomy, or where the tumor started but based on biomarkers. Biomarkers are biological parameters that we test with patients' blood or tissue before they go on the study based on the drug's mechanism. If they have a high level of these markers, they can enroll in the basket cohort, which allows us to have a shot at the goal by identifying patients who might have a higher chance of response than the population at large."

@CyclacelPharma #Cyclacel $CYCC #Onco #Oncology #Cancer #CancerResistance #CancerDrug #SolidTumor #Tumor #Fadraciclib #Fadra #CYC140 #CellCycle #Mitosis #Apoptosis

cyclacel.com

Listen to the podcast here

Spiro Rombotis is the CEO of Cyclacel, which is identifying biomarkers relevant to their drug fadraciclib's mechanism to increase the chance for success in trials for a wide range of cancers. Cyclacel has seen activity of fadra as a single agent in phase one patients with women's cancers like endometrial, ovarian, and breast cancers, and lymphomas, liver cancer, and colorectal cancer.

Spiro explains, "Before the pandemic, we had an intravenous version of fadra administered to patients in a single center study at Dana-Farber Cancer Institute in Boston. And although the drug was active in these patients, it is clear during the pandemic and now, at hopefully the tail end of the pandemic, that oral therapies have dramatic advantages. Not only because patients don't have to be exposed to the virus, which is not a very good idea for a cancer patient who is more vulnerable than the general population, but also because of the ability and convenience of receiving a drug orally and staying at home."

"We take patients regardless of tumor type, the anatomy, or where the tumor started but based on biomarkers. Biomarkers are biological parameters that we test with patients' blood or tissue before they go on the study based on the drug's mechanism. If they have a high level of these markers, they can enroll in the basket cohort, which allows us to have a shot at the goal by identifying patients who might have a higher chance of response than the population at large."

@CyclacelPharma #Cyclacel $CYCC #Onco #Oncology #Cancer #CancerResistance #CancerDrug #SolidTumor #Tumor #Fadraciclib #Fadra #CYC140 #CellCycle #Mitosis #Apoptosis

cyclacel.com

Download the transcript here

Jim Pursley is the President of Hinge Health, the leading digital health musculoskeletal (MSK) clinic that aims to reduce joint and surgical pain by deploying wearable sensors and computer-vision technology and clinical care teams. Hinge is addressing chronic and acute MSK pain with a mission to reduce the use of opioids and bring lasting relief to patients.

Jim explains, "We have the goal of alleviating pain for millions of people, not just here in the United States but around the globe. Musculoskeletal challenges, whether they be acute or chronic, account for a significant amount of the cost in today's healthcare system and also have a significant detrimental effect on the quality of life."

"As a result, what they do is they turn to other things like opioids, and surgery, which again has both a detrimental impact on their quality of life and also is a big cost driver in the country today. And so our job is to reduce the friction in this system. Whether it's the access challenge, whether it's the cost challenge or the educational challenge, our goal is to reduce that friction and make it as easy as possible to get the care you need and the outcomes you're looking for."

"So one of our missions is to really have an alternative to both opioid use and eventually elective surgery. Recognizing that sometimes surgery isn't the appropriate intervention, there's a lot of unnecessary surgery today. So we've developed Hinge with the idea that if we can deliver, again, that virtual physical therapy delivered by a physical therapist supported by a health coach and a comprehensive care team that includes orthopedic surgeons, nurse practitioners, and registered dieticians."

@HingeHealth #MSK #Musculoskeletal #DigitalHealth #PT #PhysicalTherapy #HealthandWellness #ChronicPain

Clinical Data: hingehealth.com/outcomes/

State of MSK: hingehealth.com/state-of-msk-report-2022-pdf/

Hingehealth.com

Download the transcript here

Jim Pursley is the President of Hinge Health, the leading digital health musculoskeletal (MSK) clinic that aims to reduce joint and surgical pain by deploying wearable sensors and computer-vision technology and clinical care teams. Hinge is addressing chronic and acute MSK pain with a mission to reduce the use of opioids and bring lasting relief to patients.

Jim explains, "We have the goal of alleviating pain for millions of people, not just here in the United States but around the globe. Musculoskeletal challenges, whether they be acute or chronic, account for a significant amount of the cost in today's healthcare system and also have a significant detrimental effect on the quality of life."

"As a result, what they do is they turn to other things like opioids, and surgery, which again has both a detrimental impact on their quality of life and also is a big cost driver in the country today. And so our job is to reduce the friction in this system. Whether it's the access challenge, whether it's the cost challenge or the educational challenge, our goal is to reduce that friction and make it as easy as possible to get the care you need and the outcomes you're looking for."

"So one of our missions is to really have an alternative to both opioid use and eventually elective surgery. Recognizing that sometimes surgery isn't the appropriate intervention, there's a lot of unnecessary surgery today. So we've developed Hinge with the idea that if we can deliver, again, that virtual physical therapy delivered by a physical therapist supported by a health coach and a comprehensive care team that includes orthopedic surgeons, nurse practitioners, and registered dieticians."

@HingeHealth #MSK #Musculoskeletal #DigitalHealth #PT #PhysicalTherapy #HealthandWellness #ChronicPain

Clinical Data: hingehealth.com/outcomes/

State of MSK: hingehealth.com/state-of-msk-report-2022-pdf/

Hingehealth.com

Download the transcript here